FDA Panel To Look At Controversial Electroshock Device Classification
This article was originally published in The Gray Sheet
Executive Summary
FDA's neurological devices advisory panel will meet in January to discuss the possible reclassification of devices used in electroconvulsive therapy.
You may also be interested in...
FDA Panel Endorses PMAs For Electroshock Therapy Devices
A recent vote by an FDA advisory panel favoring more stringent regulation of electroconvulsive therapy devices is not likely to jeopardize future availability of the products on the market, according the panel's chairman.
FDA Panel Endorses PMAs For Electroshock Therapy Devices
A recent vote by an FDA advisory panel favoring more stringent regulation of electroconvulsive therapy devices is not likely to jeopardize future availability of the products on the market, according the panel's chairman.
FDA Neuro Devices Panel Examines Suicide Risk In Depression Trial Subjects
Clinical trials of devices for depression do not readily lend themselves to hard-and-fast rules on when the rate of patient suicides might require a trial to be halted, according to FDA’s neurological devices panel.